Tony Keating says the company will now submit for FDA approval. Photo: Attila Csaszar

ResApp tumbles on study

Shares in medical tech firm ResApp Health have more than halved today, after the company released the preliminary results of a new US study on its technology.


(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Top 10 Shareholders

Source: Morningstar

Total Shareholder Return as at 28/06/19

1 year TSR5 year TSR
103rdResApp Health44%118%
304thVDM Group0%-28%
678thSUDA Pharmaceuticals-57%-41%
725thSky and Space Global-65%14%
731 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

$65k Bought
$49k Bought
$49k Other
Total value as at the date of the transaction
Source: Morningstar


136th↑ResApp Health$999k
147th↑xTV Networks$561k
148th↓VDM Group$561k
150th↑Sky and Space Global$503k
151st↓SUDA Pharmaceuticals$488k
198 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer